Literature DB >> 18223319

Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.

Ximing J Yang1, Ming Zhou, Ondrej Hes, Steven Shen, Rongshan Li, Jose Lopez, Rajal B Shah, Yu Yang, Shang-Tian Chuang, Fan Lin, Maria M Tretiakova, Eric J Kort, Bin Tean Teh.   

Abstract

The nature of tubulocystic carcinoma, a rare renal tumor composed of tubular and cystic structures, is poorly understood. It has been suggested that it may represent a low-grade collecting duct carcinoma of the kidney despite the lack of sufficient molecular and pathologic evidence. The aim of this study was to examine the clinical and pathologic features of 13 cases of tubulocystic carcinoma of the kidney. Furthermore, using gene expression microarray analysis, we defined the molecular signature of this tumor by comparing it with other renal tumors in our previously established molecular profile database. Histologically, all 13 tumors were composed of closely packed tubules and cysts of varying sizes separated by fibrovascular septa. The epithelial lining cells of the tubules and cysts in this tumor were characterized by abundant eosinophilic cytoplasm with prominent nucleoli often showing a hobnail appearance. Clinically, one of the 13 cases showed metastasis to the pelvic lymph nodes. Five of the 13 cases coexisted with papillary renal cell carcinoma (RCC) (n=3) or papillary adenoma (n=2). In addition, the molecular profile of tubulocystic carcinoma was similar but not identical to those of papillary RCC by clustering analysis. Through comparative genomic microarray analysis, tubulocystic carcinoma showed gains of chromosome 17, but not chromosome 7, whereas most papillary RCCs showed chromosomal gains in both 7 and 17 (trisomies). Therefore, based on its unique pathologic features and molecular signature as well as its biologic behavior to develop metastasis either by itself or in association with papillary RCC, tubulocystic carcinoma of the kidney should be recognized as a distinct subtype of RCC and be distinguished from other malignant and benign cystic lesions of the kidney.

Entities:  

Mesh:

Year:  2008        PMID: 18223319     DOI: 10.1097/PAS.0b013e318150df1d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Authors:  G Kristiansen; B Delahunt; J R Srigley; C Lüders; J-M Lunkenheimer; H Gevensleben; T Thiesler; R Montironi; L Egevad
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 2.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

3.  Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Steven C Smith; Kiril Trpkov; Ying-Bei Chen; Rohit Mehra; Deepika Sirohi; Chisato Ohe; Andi K Cani; Daniel H Hovelson; Kei Omata; Jonathan B McHugh; Wolfram Jochum; Maurizio Colecchia; Mitual Amin; Mukul K Divatia; Ondřej Hes; Santosh Menon; Isabela Werneck da Cunha; Sergio Tripodi; Fadi Brimo; Anthony J Gill; Adeboye O Osunkoya; Cristina Magi-Galluzzi; Mathilde Sibony; Sean R Williamson; Gabriella Nesi; Maria M Picken; Fiona Maclean; Abbas Agaimy; Liang Cheng; Jonathan I Epstein; Victor E Reuter; Satish K Tickoo; Scott A Tomlins; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

4.  Tubulocystic Renal Cell Carcinoma: A Great Imitator.

Authors:  Indraneel Banerjee; Sher Singh Yadav; Vinay Tomar; Suresh Yadav; Shyam Talreja
Journal:  Rev Urol       Date:  2016

Review 5.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

6.  Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.

Authors:  Petr Steiner; Milan Hora; Jan Stehlik; Petr Martinek; Tomas Vanecek; Fredrik Petersson; Michal Michal; Marie Korabecna; Ivan Travnicek; Ondrej Hes
Journal:  Virchows Arch       Date:  2013-01-08       Impact factor: 4.064

7.  Tubulocystic carcinoma of the kidney.

Authors:  Varsha Podduturi; Carol F Adair; Haiying Zhang
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-07

Review 8.  Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.

Authors:  Ming Zhao; Xiaodong Teng; Guoqing Ru; Zhongsheng Zhao; Qinqin Hu; Likai Han; Xianglei He
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Tubulocystic carcinoma of the kidney: a histologic, immunohistochemical, and ultrastructural study.

Authors:  Borislav A Alexiev; Cinthia B Drachenberg
Journal:  Virchows Arch       Date:  2013-03-24       Impact factor: 4.064

Review 10.  Renal cell carcinoma: Evolving and emerging subtypes.

Authors:  Suzanne M Crumley; Mukul Divatia; Luan Truong; Steven Shen; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2013-12-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.